Hepatocellular carcinoma after prior sorafenib treatment: incidence, healthcare utilisation and costs from German statutory health insurance claims data

OBJECTIVE: To estimate both the number of patients with hepatocellular carcinoma (HCC) eligible annually for second-line therapy following sorafenib in Germany and the healthcare costs accrued by patients meeting eligibility criteria. METHODS: Patients with an HCC diagnosis and one or more sorafenib...

Descripción completa

Detalles Bibliográficos
Autores principales: Clouth, Johannes, Liepa, Astra M., Moeser, Guido, Friedel, Heiko, Bernzen, Magdalena, Trojan, Jörg, Garal-Pantaler, Elena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2018
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6111015/
https://www.ncbi.nlm.nih.gov/pubmed/30151607
http://dx.doi.org/10.1186/s13561-018-0199-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6111015/
https://www.ncbi.nlm.nih.gov/pubmed/30151607
http://dx.doi.org/10.1186/s13561-018-0199-1

Ejemplares similares